Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 327

Sort by

Sort Order Select

Journal Articles

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Blood (2025) 146 (7): 834–846.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood (2025) 145 (5): 497–507.

https://doi.org/10.1182/blood.2024025563

Published: 2025

Includes: Supplemental data

Journal Articles

The current landscape of frontline large B-cell lymphoma trials

David Qualls, Philippe Armand, Gilles Salles

Blood (2025) 145 (2): 176–189.

https://doi.org/10.1182/blood.2023023789

Published: 2025

Journal Articles

Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Muhit Ozcan, Won Seog Kim, Huilai Zhang, Maria Bouzani, Zsolt Nagy, Hun Chuah, Gilles Salles, Edwin E. Jeng, Jiangeng Huang, Mariana Sacchi, Yajian Jiang, Adrian Minson

Blood (2024) 144 (Supplement 1): 4502.1.

https://doi.org/10.1182/blood-2024-198700

Published: 2024

Journal Articles

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Blood (2024) 144 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2024-210657

Published: 2024

Journal Articles

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Brandon S. Imber, Anna Brosoff, Emma Roszak, Devin McAvoy, Kinga K. Hosszu, Alexander P. Boardman, Parastoo B Dahi, Gunjan L. Shah, Michael Scordo, Jae H. Park, Miguel-Angel Perales, Gilles Salles, Maria Lia Palomba, Joachim Yahalom

Blood (2024) 144 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2024-210156

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas

Anu Amallraja, Gunes Gundem, Dylan Domenico, Juan E Arango Ossa, Umut Aypar, Jeeyeon Baik, Michael Kluk, Shenon Sethi, Katherine Lopez, David A. Qualls, Gilles Salles, Elli Papaemmanuil, Pallavi Galera, Ahmet Dogan

Blood (2024) 144 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2024-203770

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Journal Articles

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Blood (2024) 144 (Supplement 1): 569.

https://doi.org/10.1182/blood-2024-202537

Published: 2024

Journal Articles

A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL

Blood (2024) 144 (Supplement 1): 740.

https://doi.org/10.1182/blood-2024-209642

Published: 2024

Journal Articles

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Ariela Noy, Win Su Thet, Shreya Vemuri, Venkatraman Seshan, Connie Lee Batlevi, Zachary D. Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Thomas M. Habermann, Paul A. Hamlin, Erel Joffe, Jennifer Kimberly Lue, Matthew Matasar, Maria Lia Palomba, Andrew D. Zelenetz, Gilles Salles

Blood (2024) 144 (Supplement 1): 6352.

https://doi.org/10.1182/blood-2024-211730

Published: 2024

Journal Articles

Comparison of Progression-Free Survival of Relapsed or Refractory Follicular Lymphoma Patients in a Single-Arm Trial of Tazemetostat with a Real-World External Control Arm

Gilles Salles, John P. Leonard, Franck Morschhauser, Aaron Crowley, Alexandra Z. Sosinsky, Camryn Lieb, Bret Zeldow, Joanna Harton, Shu Wang, John Boyer, Vitalii Doban, Marion Bonnet, Valerie Perrot, Kylee Jordan Veazey

Blood (2024) 144 (Supplement 1): 6347.

https://doi.org/10.1182/blood-2024-208702

Published: 2024

Journal Articles

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Blood (2024) 144 (Supplement 1): 4434.

https://doi.org/10.1182/blood-2024-210689

Published: 2024

Journal Articles

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2024-203857

Published: 2024

Journal Articles

Very Low Dose Radiotherapy (VLDRT) with 4 Gy for Potentially-Curable Indolent Non-Hodgkin Lymphomas

Nikhil P. Mankuzhy, Brandon S. Imber, Paige Pammer, Beatrice Fregonese, Adriana Cajo, Gustav Cederquist, Alexandra Dreyfuss, Kaitlyn Lapen, Roshal R. Patel, Zachary R. Moore, Carla Hajj, Gilles Salles, Joachim Yahalom

Blood (2024) 144 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2024-208916

Published: 2024

Journal Articles

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2024-203807

Published: 2024

Journal Articles

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 238.

https://doi.org/10.1182/blood-2024-192995

Published: 2024

Journal Articles

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Blood (2024) 144 (Supplement 1): 781.

https://doi.org/10.1182/blood-2024-200915

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

The current landscape of frontline large B-cell lymphoma trials

Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Comparison of Progression-Free Survival of Relapsed or Refractory Follicular Lymphoma Patients in a Single-Arm Trial of Tazemetostat with a Real-World External Control Arm

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Very Low Dose Radiotherapy (VLDRT) with 4 Gy for Potentially-Curable Indolent Non-Hodgkin Lymphomas

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only